The problem that keeps engineers up at 2 a.m.
Stuff inside a device can quietly betray you — adhesives that weep plasticizers, tubing that blooms extractables after sterilization, seals that don’t play nice with saline. That’s the practical headache: chemistry meets motion meets heat, and the result can be flaky performance or a regulatory delay. If you design devices or partner with manufacturers, early conversations with your medical device contract manufacturing team save more time than late-stage testing ever will.
How materials fail, in plain terms
Polymers aren’t inert. Additives migrate. Sterilization changes surface energy. Metals corrode. Those things show up as extractables in aggressive solvents and as leachables in patient-contact fluids. Small surprises become big problems when they alter drug stability, sensor readings, or trigger a biological response. Predictable mechanisms — swelling, sorption, depolymerization — explain most issues. Fix those, and you’re already ahead.
Testing that actually answers questions
Separate extractables from leachables: extractables are what you can pull out under harsh conditions; leachables are what actually escapes under realistic use. Use GC‑MS for volatiles, LC‑MS for less volatile organics, and ICP‑MS for metals. Run simulated-use fluids, time points that reflect shelf life and worst-case patient exposure, and assemblies, not just raw resin. Common mistakes: wrong solvent, too-short exposure, and testing components in isolation when the assembly chemistry matters.
Design choices that reduce risk
Pick materials for the job: fluoropolymers resist most solvents and often reduce leachables; medical-grade silicones and PEEK can be better choices than general-purpose plastics. Minimize mixed-material interfaces where different polymers or adhesives meet. Where adhesives are necessary, choose those with proven extractables profiles and validate them after sterilization. Small concessions in design — thicker barriers, fewer adhesives, sealed joints — pay dividends during verification and regulatory review.
Where experience counts
Practical knowledge comes from doing this across products and events that shape the industry. Engineers at trade shows like MD&M West in Anaheim often share case studies about assemblies that failed only after sterilization, a recurring theme in device circles; that kind of field feedback informs sensible test plans and material choices and helps with biomedical device integration. Standards and guidance — ISO 10993 series, FDA documents on extractables/leachables — back those lessons and are worth reading with actual project data in hand.
Common pitfalls teams repeat
Relying on supplier datasheets alone. Testing unassembled parts and assuming the assembly behaves the same. Ignoring sterilization or accelerated aging effects. Using inappropriate analytical limits or skipping control matrices. All of these look innocent until a stability study or clinical test says otherwise.
A compact checklist you can act on
1) Define worst-case contact scenarios and fluids. 2) Build a materials compatibility matrix early. 3) Run extractables under aggressive conditions and targeted leachables under simulated use. 4) Include sterilized assemblies and aged samples. 5) Review results against clinical relevance, not just detection limits. 6) Document supplier qualifications and change control. 7) Bring manufacturers into the loop early.
A practical close
Fix the small chemistry problems before they become clinical or regulatory ones. That’s the whole point: test thoughtfully, choose materials deliberately, and validate with real-use conditions. For teams that want a practical partner who’s been through those iterations, groups like kingsin often end up consulted early because they combine lab rigor with manufacturing sense, and that combination keeps devices moving forward without last-minute surprises.

